InMed Pharmaceuticals: Fairmount holds 10.6M shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
InMed Pharmaceuticals Inc. (INM) reports that Fairmount Healthcare Fund II L.P. indirectly held 10,555,507 common shares as of November 6, 2026, following a merger exchange effective that day. The fund also held 4,013 shares of Series A non-voting convertible preferred stock representing 4,013,000 underlying common shares, plus pre-funded warrants for 1,468,222 common shares exercisable at $0.0001 each.
Fairmount Funds Management LLC, Peter Evan Harwin and Tomas Kiselak are also identified as ten-percent owners. They disclaim beneficial ownership except to the extent of their pecuniary interest. The preferred stock and warrants carry 19.99% beneficial-ownership limits; the preferred-stock limit automatically becomes 9.99% when ownership is 9.00% or less.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Series A Non-Voting Preferred Stock F4, F5, F1, F6, F3 | -- | -- | -- |
| Holding | Pre-funded Warrant F7, F8, F1, F9, F3 | -- | -- | -- |
| Holding | Common Stock F1, F2, F3 | -- | -- | -- |
Footnotes (9)
- F1. Effective as of November 6, 2026 (the "Effective Time"), (i) Indigo Merger Sub Corp., a wholly owned subsidiary of Mentari Therapeutics, Inc. (formerly known as InMed Pharmaceuticals Inc.), a Nevada corporation (the "Issuer"), merged with and into Mentari Therapeutics, Inc., a Delaware corporation ("Pre-Merger Mentari"), with Pre-Merger Mentari continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC, a second wholly owned subsidiary of the Issuer ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Mentari Therapeutics Operating Company LLC (the "Second Merger" and, together with the First Merger, the "Merger").
- F2. Represents the number of shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Mentari's common stock and Series A Preferred Stock held by the Reporting Person prior to the Merger. Each share of Pre-Merger Mentari's common stock and Series A Preferred Stock held at the Effective Time was exchanged for 0.20065 shares of the Issuer's common stock.
- F3. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. Peter Harwin and Tomas Kiselak are the managers of Fairmount. Fairmount, Mr. Harwin and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- F4. Series A Non-Voting Convertible Preferred Stock of the Issuer, par value $0.0001 per share (the "Issuer Preferred Stock"), has no expiration date and is convertible at any time and from time to time at the option of the holder thereof into a number of shares of the Issuer's common stock equal to the Conversion Ratio, initially 1,000 shares of common stock for each share of Issuer Preferred Stock, subject to adjustment. A holder may not convert Issuer Preferred Stock to the extent that, after giving effect to the conversion, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, including any group of which the holder is a member, would beneficially own shares of common stock in excess of the applicable beneficial ownership limitation, which the Reporting Person has designated as 19.99% of the shares of common stock outstanding.
- F5. (Continued from footnote 4) A holder may reset that limitation to a lower percentage effective immediately, or to a higher percentage not exceeding 19.99% effective on the 61st day after written notice to the Issuer, and the limitation is automatically set at 9.99% at any time the holder's beneficial ownership is 9.00% or less of the outstanding common stock.
- F6. Represents the number of shares of the Issuer's common stock underlying 4,013 shares of Issuer Preferred Stock received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Mentari's Series Seed Preferred Stock ("Mentari Series Seed Preferred Stock") held by the Reporting Person prior to the Merger. Each share of Mentari Series Seed Preferred Stock held at the Effective Time was exchanged for 0.00020065 shares of Issuer Preferred Stock.
- F7. The pre-funded warrants to purchase shares of the Issuer's common stock (the "Issuer Pre-Funded Warrants") have no expiration date and are exercisable at any time and from time to time on or after the date of issuance. A holder may not exercise the Issuer Pre-Funded Warrants to the extent that, immediately prior to or following the exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated with the holder's for purposes of Section 13(d) of the Securities Exchange Act of 1934, would beneficially own shares of common stock in excess of the maximum percentage applicable to such holder, which the Reporting Person has elected to be 19.99% of the shares of common stock issued and outstanding following the exercise.
- F8. (Continued from footnote 7) A holder may increase or decrease that maximum percentage by written notice to the Issuer, provided that it may not exceed 19.99% and that any increase is not effective until the 61st day after the notice is delivered to the Issuer.
- F9. Represents the number of Issuer Pre-Funded Warrants received by the Reporting Person in the Merger in exchange for pre-funded warrants to purchase shares of Pre-Merger Mentari's common stock (the "Mentari Pre-Funded Warrants") held by the Reporting Person prior to the Merger. Each Mentari Pre-Funded Warrant held at the Effective Time was exchanged for 0.20065 Issuer Pre-Funded Warrants.
Key Figures
Key Terms
beneficial ownership limitation regulatory
Conversion Ratio technical
pre-funded warrants financial
pecuniary interest financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership limits apply to INM preferred stock and warrants?
AI-generated analysis. How Rhea-AI works. Not financial advice.